Inhibition by Somatostatin of ACTH Secretion in Nelson's Syndrome

Overview

Journal J Clin Endocrinol Metab

Publisher Oxford University Press

Specialty Endocrinology

Date 1975 Jun 1

PMID 166089

Citations 24

Authors

J B Tyrrell

M Lorenzi

J E Gerich

P H FORSHAM

Affiliations

Soon will be listed here.

Abstract

Somatostatin (GHIF), when administered as a 1-hr infusion (500 mug/hr) to 5 patients with Nelson's Syndrome;resulted in a sustained, progressive fall in plasma ACTH in each patient to 40% to 71% of basal values with a return toward initail levels after cessation of the infusion. The meanreduction in plasma ADTH was 48% (p less than 0.005). These finding suggest that GHIF receptors not fuctional or present in normal pituitary tissue are present in ACTH-producing pituitary tumors.

Citing Articles

Management of Nelson's Syndrome.

Fountas A, Karavitaki N Medicina (Kaunas). 2022; 58(11).

PMID: 36363537 PMC: 9697743. DOI: 10.3390/medicina58111580.

Glucocorticoid Receptor Antagonism Upregulates Somatostatin Receptor Subtype 2 Expression in ACTH-Producing Neuroendocrine Tumors: New Insight Based on the Selective Glucocorticoid Receptor Modulator Relacorilant.

Pivonello R, Munster P, Terzolo M, Ferrigno R, Simeoli C, Puglisi S Front Endocrinol (Lausanne). 2022; 12:793262.

PMID: 35058882 PMC: 8764187. DOI: 10.3389/fendo.2021.793262.

Rapid response of Nelson's syndrome to pasireotide in radiotherapy-naive patient.

He X, Spencer-Segal J Clin Diabetes Endocrinol. 2020; 6(1):22.

PMID: 33292741 PMC: 7648374. DOI: 10.1186/s40842-020-00110-7.

Role of "old" pharmacological agents in the treatment of Cushing's syndrome.

Ambrogio A, Cavagnini F J Endocrinol Invest. 2016; 39(9):957-65.

PMID: 27086313 PMC: 4987391. DOI: 10.1007/s40618-016-0462-4.

New avenues in the medical treatment of Cushing's disease: corticotroph tumor targeted therapy.

Fleseriu M, Petersenn S J Neurooncol. 2013; 114(1):1-11.

PMID: 23673515 PMC: 3724972. DOI: 10.1007/s11060-013-1151-1.